olsalazine sodium
Current shortage
The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
The TGA has assessed this shortage as medium impact, meaning some people may need to change brand, strength or product while it lasts.
2 product records on the Australian Register of Therapeutic Goods, listed in full below. The TGA last updated this information on 9 May 2022. Not medical advice.
The TGA does not publish a reason for a shortage, so Voxsanity cannot show one. Nothing on this page is an explanation of why supply is affected — that information is not in the source and is not inferred here.
This is national information. The TGA records shortages for Australia as a whole. There is no state, territory or pharmacy-level stock information in this data, and Voxsanity cannot tell you whether a particular pharmacy has a medicine in stock. Your pharmacist can.
olsalazine sodium is subsidised on the PBS. The active ingredient is on the current Pharmaceutical Benefits Scheme, so it is a medicine dispensed under subsidy across Australia rather than one supplied through a narrower route. That is a fact about how widely it is used, not a rating of how serious this shortage is — the TGA's own impact rating above is the only severity statement on this page, and this does not change it.
A PBS listing is recorded against the active ingredient, while a shortage is usually reported against particular brands, strengths or pack sizes. So a subsidised alternative brand of the same ingredient may still be available even where a shortage is open. Your pharmacist can tell you what is in stock and can discuss substitutions with your prescriber.
PBS-subsidised for: Crohn's Disease and Colitis. That is what the Pharmaceutical Benefits Scheme records the subsidy for olsalazine sodium against, not the full range of conditions it is used for. A medicine subsidised under an indication Voxsanity has not mapped to a condition page, or used for a condition without a PBS subsidy for it, does not appear here — so this list understates what the medicine is used for and can never overstate it.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Products affected
DIPENTUM olsalazine sodium 500mg tablet bottle
Tablet, uncoated · ARTG 53582
- Status
- Current shortage The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
- Supply
- Unavailable The supplier reports no stock is available.
- TGA impact rating
- Medium impact The TGA has assessed this shortage as medium impact, meaning some people may need to change brand, strength or product while it lasts.
- Reported from
- 11 October 2022 The TGA's dates span 4 years, 1 month.
- Expected to be resolved
- 31 October 2026 This is the date the supplier has given the TGA. It can move.
- TGA last updated
- 9 May 2022
What the TGA says is being done
Patients are advised to consult their health professional to discuss alternative treatment options.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
DIPENTUM olsalazine sodium 250mg capsule bottle
Capsule · ARTG 14466
- Status
- Current shortage The TGA records this medicine as being in shortage now. A shortage often affects some brands, strengths or pack sizes and not others, so a supply of the medicine may still be available. Your pharmacist can tell you what is in stock and what alternatives exist.
- Supply
- Unavailable The supplier reports no stock is available.
- TGA impact rating
- Low impact The TGA has assessed this shortage as low impact, meaning alternatives are generally available and most people can be managed without difficulty.
- Reported from
- 4 February 2021 The TGA's dates span 5 years, 9 months.
- Expected to be resolved
- 31 October 2026 This is the date the supplier has given the TGA. It can move.
- TGA last updated
- 1 December 2020
What the TGA says is being done
Patients are advised to consult their healthcare professional to discuss alternative treatment options.
Quoted from the TGA's own record for this product. Voxsanity has not edited, summarised or interpreted it.
Where this comes from
Source: Medicine Shortage Reports Database, Therapeutic Goods Administration (TGA), © Commonwealth of Australia, reproduced with permission. The TGA does not endorse Voxsanity, and nothing here is presented as a TGA view. Shortage information is free for everyone on this site, with no account and no subscription.
To read the TGA's own entry for olsalazine sodium, open the TGA Medicine Shortage Reports Database and type olsalazine sodium into its filter box. The TGA's register has no direct link to an individual medicine, so this is the closest link that exists. General information about medicine shortages is on the TGA's medicine shortages page.
Voxsanity last read the register on 18 August 2026.
Not medical advice. Voxsanity republishes public government health data in plain English. Speak to your pharmacist or doctor about your own medicines. Do not stop or change how you take a medicine because of anything on this page.